Connecting Phage world
A global phage summit bringing together biotech and pharma innovators, clinicians, regulators, pharmacists, industry leaders and researchers to advance phage therapy and combat antimicrobial resistance.
May 19-21
Ljubljana, Slovenia | Grand Hotel Union
We envision a world where phage therapy is a practical, accessible solution for patients facing bacterial infections, including those resistant to antibiotics. By learning from clinical outcomes and compassionate-use experiences, we aim to transform phage innovations into real-world treatments. Our vision is to:
- Connect a global community of phage professionals dedicated to improving patient care.
- Translate clinical insights into patient-centered and actionable solutions.
- Raise awareness among clinicians and healthcare institutions about the potential of phage therapy.
- Combat antimicrobial resistance with safe and effective phage treatments.
- Empower the global phage community to turn knowledge into impact.
- Together, we are committed to transforming phage therapy from promise into practice - delivering safe, effective and accessible treatments to patients worldwide.
JAFRAL – supplying phage products of highest quality and enabling therapy worldwide.
- World's leading phage manufacturer
- Building bridges between key stakeholders in phage therapy
- Supporting the global fight against AMR
A summit for anyone shaping or exploring the future of phage application and AMR solutions:
- Pharma and biotech professionals
- Doctors, clinicians and infectious disease specialists
- Regulators
- Community & clinical pharmacists
- Researchers and scientists
- Students and emerging professionals
Whether you’re an established expert or a newcomer, everyone gains unique opportunities to connect and collaborate.
Engage with global experts, industry innovators, clinicans and leading scientists driving innovation in phage therapy worldwide.
Intralytix, Inc.
Alexander “Sandro” Sulakvelidze, PhD, is the president and CEO of Intralytix and a globally recognized expert in phage technology. He co-founded the company and led its growth into a clinical-stage firm with FDA-approved products and ongoing clinical trials.
Phiogen Pharma
Amanda Burkardt is a commercialization expert with 15+ years of experience bridging science and business. At PHIOGEN, she leads global commercialization of next-generation phage therapies for deadly bacterial infections.
MHRA
Dr. Carmen Coxon is a biotherapeutics specialist at the MHRA, working at the intersection of novel antimicrobials, AMR and regulatory science. She maps emerging One Health products and supports developers in navigating regulatory and access challenges across the product lifecycle.
SNIPR Biome
Dr. Christian Grøndahl is CEO, Founder and Director of SNIPR BIOME, a clinical-stage biotech developing CRISPR-based microbiome therapies. He is a Doctor of Medical Science, holds an MBA, and has over 30 years of executive experience in the biotech industry.
PhagePro
Dr. Minmin Yen is CEO and Co-founder of PhagePro, developing bacteriophage solutions to combat antimicrobial resistance. Dr. Yen has been recognized with honors including MIT Technology Review’s 35 Innovators Under 35, Boston Business Journal’s Women Who Mean Business, and the Henri Termeer Legacy Fellowship.
EMA
Dr. Radu Botgros is an infectious diseases specialist and Senior Scientific Officer at the European Medicines Agency. He focuses on anti-infectives, antimicrobial resistance, and regulatory aspects of medicines addressing public health threats.
Three days of tailored sessions exploring current clinical trials, compassionate use cases and their outcomes and discussions on the global AMR challenge.
Day 1
Clinical studies in progress – early results, insights and discussions
Day 2
Compassionate use cases & magistral preparations
Day 3
Global AMR landscape & bacterial infectious disease strategies
